Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) - Detection and diagnosis

This action is expected to increase the preparedness of the Union to respond to CBRN threats and improve the availability of medical countermeasures against these threats. It should advance one or more medical countermeasures against CBRN threats along the steps towards regulatory approval and market readiness. In particular:

• For detection and diagnostics, a special focus is on tests that can rapidly detect individual or broad range of chemical and biological agents, including biotoxins.

The range of activities include an end-to-end approach to bridge the gap between advanced research, innovation, market access and deployment by supporting:

• Advanced research and development (‘R&D’) to support the development of medical countermeasures;

• Involving end users and security practitioners to bring the research products closer to market readiness; and

• Support research into market readiness or facilitate tech and entrepreneurial skills development.

The objective is to improve the Union’s readiness to respond to intentional health threats, including cross-border ones, by supporting the development of medical countermeasures to biological, chemical and radio-nuclear agents for which there currently are no or only limited treatment options.

This action will focus on supporting advanced research on threat-agnostic medical countermeasures against CBRN agents and platform approaches to treat injuries from CBRN agents.